Here's the platelet/blood article as printed in Korea. Take note the pride of the Korean based media's spin as opposed to the U.S. version of the story. Advanced Cell does get a mention though.
At the end of the article there is a value assigned for the Global market of blood/blood elements.
I wonder how Lanza divides all his time up. He must be flying back and forth, running around like a mad-man trying to move forward with all these trials, keep CHA happy, make new discoveries. How would you like to find yoursel sitting next to Lanza on the plane ride to SK? That would be cool!
From the Google Board:
Blood can not be transfused cross specie. Platelets, on the other hand can
be tested on animals. The key word in this PR is "indistinguishable" between
the "donated platelets" vs. "differentiated platelets". On this basis, we
can assume that it will work with Humans both for Blood and Platelets.
This will be an easy and short FDA approval.
The hard part is Technology Transfer from the Labs to the Factory Floor.
But, if anybody can do this... the Koreans can.
This by itself is huge, and you will see SCRMI become a multibillion dollar
partnership within 3 to 5 years. This will now explain why Samsung is very
interested in partnering with CHA.
Note that they next target is Bone Marrow transplantation. This is a mega
billion market. The good thing is, if you can do blood and platelets, you
can do Bone Marrow!
By the way, I am not so sure now that ACTC is counting this 2 prospective
trials as their own.
It is very possible that ACTC's hemangioblast reference is to PAD. They have
already done animal testing on this one. If it is... so much the better, and
it is also huge!